Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Detection of circulating tumor cells in breast cancer patients: prognostic predictive role.

Turker I, Uyeturk U, Sonmez OU, Oksuzoglu B, Helvaci K, Arslan UY, Budakoglu B, Alkis N, Aksoy S, Zengin N.

Asian Pac J Cancer Prev. 2013;14(3):1601-7.

2.

Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.

Hepp P, Andergassen U, Jäger B, Trapp E, Alunni-Fabbroni M, Friedl TW, Hecker N, Lorenz R, Fasching P, Schneeweiss A, Fehm T, Janni W, Rack B.

Anticancer Res. 2016 Sep;36(9):4771-6.

PMID:
27630326
3.

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.

Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T; DETECT study group.

Breast Cancer Res. 2012 Aug 15;14(4):R118. doi: 10.1186/bcr3243.

4.

Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.

Chang K, Kong YY, Dai B, Ye DW, Qu YY, Wang Y, Jia ZW, Li GX.

Oncotarget. 2015 Dec 8;6(39):41825-36. doi: 10.18632/oncotarget.6167.

5.

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.

Bidard FC, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Cottu P, Beuzeboc P, Rolland E, Mathiot C, Pierga JY.

Breast Cancer Res. 2012 Feb 13;14(1):R29.

6.

Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.

Jueckstock J, Rack B, Friedl TW, Scholz C, Steidl J, Trapp E, Tesch H, Forstbauer H, Lorenz R, Rezai M, Häberle L, Alunni-Fabbroni M, Schneeweiss A, Beckmann MW, Lichtenegger W, Fasching PA, Pantel K, Janni W; SUCCESS Study Group.

BMC Cancer. 2016 Jul 7;16:401. doi: 10.1186/s12885-016-2454-3.

7.

Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.

Hall C, Karhade M, Laubacher B, Anderson A, Kuerer H, DeSynder S, Lucci A.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S552-8. doi: 10.1245/s10434-015-4600-6. Epub 2015 May 13.

PMID:
25968619
8.
9.

A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.

Barbazán J, Muinelo-Romay L, Vieito M, Candamio S, Díaz-López A, Cano A, Gómez-Tato A, Casares de Cal Mde L, Abal M, López-López R.

Int J Cancer. 2014 Dec 1;135(11):2633-43. doi: 10.1002/ijc.28910. Epub 2014 Apr 29.

10.

Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.

Iwata H, Masuda N, Yamamoto D, Sagara Y, Sato N, Yamamoto Y, Saito M, Fujita T, Oura S, Watanabe J, Tsukabe M, Horiguchi K, Hattori S, Matsuura Y, Kuroi K.

Breast Cancer Res Treat. 2017 Apr;162(3):501-510. doi: 10.1007/s10549-017-4138-3. Epub 2017 Feb 8.

PMID:
28181129
11.

High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.

Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Diéras V, Rolland E, Mignot L, Mathiot C, Bidard FC.

Ann Oncol. 2012 Mar;23(3):618-24. doi: 10.1093/annonc/mdr263. Epub 2011 Jun 3.

PMID:
21642515
12.

Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.

Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, Cristofanilli M.

Breast Cancer Res Treat. 2015 Dec;154(3):563-71. doi: 10.1007/s10549-015-3636-4. Epub 2015 Nov 16.

PMID:
26573830
13.

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.

Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, Marty M, Pierga JY.

Ann Oncol. 2010 Apr;21(4):729-33. doi: 10.1093/annonc/mdp391. Epub 2009 Oct 22.

PMID:
19850639
14.

[Prediction value for dynamic changes of circulating tumor cell in therapeutic response and prognosis of Chinese metastatic breast cancer patients].

Bian L, Liu Y, Wang T, Zhang S, Shao Z, Tong Z, Song E, Wang X, Liao N, Jiang Z.

Zhonghua Yi Xue Za Zhi. 2014 Jan 28;94(4):265-8. Chinese.

PMID:
24731491
15.

The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.

Zhou J, Dong F, Cui F, Xu R, Tang X.

Cancer Chemother Pharmacol. 2017 Apr;79(4):825-833. doi: 10.1007/s00280-017-3269-x. Epub 2017 Mar 13.

PMID:
28289866
16.

Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.

Ušiaková Z, Mikulová V, Pintérová D, Brychta M, Valchář J, Kubecová M, Tesařová P, Bobek V, Kološtová K.

In Vivo. 2014 Jul-Aug;28(4):605-14.

PMID:
24982230
17.

Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.

Shiomi-Mouri Y, Kousaka J, Ando T, Tetsuka R, Nakano S, Yoshida M, Fujii K, Akizuki M, Imai T, Fukutomi T, Kobayashi K.

Breast Cancer. 2016 Jan;23(1):120-7. doi: 10.1007/s12282-014-0539-x. Epub 2014 Jun 7.

PMID:
24906662
18.

The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.

Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer EF, Müller V, Janni W, Schneeweiss A, Fehm TN.

Breast Cancer Res Treat. 2013 Jan;137(2):503-10. doi: 10.1007/s10549-012-2382-0. Epub 2012 Dec 28.

PMID:
23271327
19.

Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.

Deutsch TM, Riethdorf S, Nees J, Hartkopf AD, Schönfisch B, Domschke C, Sprick MR, Schütz F, Brucker SY, Stefanovic S, Sohn C, Pantel K, Trumpp A, Schneeweiss A, Wallwiener M.

Breast Cancer Res Treat. 2016 Nov;160(2):277-290. Epub 2016 Oct 1.

PMID:
27696083
20.

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.

Wallwiener M, Hartkopf AD, Riethdorf S, Nees J, Sprick MR, Schönfisch B, Taran FA, Heil J, Sohn C, Pantel K, Trumpp A, Schneeweiss A.

BMC Cancer. 2015 May 14;15:403. doi: 10.1186/s12885-015-1423-6.

Supplemental Content

Support Center